Attention Disorders Therapeutics
1. Strattera patent expiration
Treatment: Treatment of attention-deficit hyperactivity disorder
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5658590 (Pediatric) | LILLY | Treatment of attention-deficit/hyperactivity disorder |
May, 2017
(8 years ago) | |
| US5658590 | LILLY | Treatment of attention-deficit/hyperactivity disorder |
Nov, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-78) | Jul 23, 2011 |
Drugs and Companies using ATOMOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 November, 2002
Dosage: CAPSULE
How can I launch a generic of STRATTERA before it's drug patent expiration?
More Information on Dosage
STRATTERA family patents
